Pictured: Woman grasping her stomach in pain/iStock, Doucefleur The use of glucagon-like peptide 1 (GLP-1) agonists for weight loss, such as Novo Nordisks Ozempic and Wegovy, is associated with the risk of gastrointestinal adverse events, according to a study published Thursday in the medical journal JAMA
Each pathway contributes a separate pharmacological signal: GLP-1 receptor agonism slows gastric emptying and reduces appetite signalling in the hypothalamus GIP receptor agonism enhances glucose-dependent insulin secretion and is associated in the literature with effects on lipid handling Glucagon receptor agonism increases energy expenditure and hepatic glucose output, the opposite direction to a glucagon antagonist, and is absent from every dual agonist currently on the UK market How retatrutide compares to dual agonists Tirzepatide (Mounjaro) is a GIP + GLP-1 dual agonist authorised by the MHRA for type 2 diabetes in 2023
Heres how to choose what suits you best: Beginners : Start with pure creatine monohydrate powder to build a performance base
Pricing is dosedependent : Lower doses (2.5 mg, 5 mg): ~ $301/month Higher doses (10 mg, 12.5 mg, 15 mg): ~ $502/month Across all dose levels, Mounjaro is more expensive than Ozempic